BI 2536

Catalog No.S1109

BI 2536 Chemical Structure

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 56 Publications

13 Customer Reviews

  • (C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

    Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

    Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.

  • (a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

    Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

    (a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

    Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.

  • Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm3 tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

     

     

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    animals with 50- to 100-mm3 tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

    Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

    Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.

  • Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

    J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

  • Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Targets
PLK1 [1]
(Cell-free assay)
PLK2 [1]
(Cell-free assay)
PLK3 [1]
(Cell-free assay)
0.83 nM 3.5 nM 9.0 nM
In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PSN1 NHzUZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3JTWM2OD1yLkCwO|c3KM7:TR?= NXTrOFg6W0GQR1XS
ACN NX;0VFl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX6ZYtKSzVyPUCuNFA5PDNizszN NHPUS3JUSU6JRWK=
TE-8 NXL4cXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEC5OFEh|ryP MWDTRW5ITVJ?
LC-2-ad M4HRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXWTWM2OD1yLkCxNFk{KM7:TR?= MoHmV2FPT0WU
ALL-PO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPO[GxKSzVyPUCuNFE{KM7:TR?= NGHhbGNUSU6JRWK=
EW-16 M4LzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nC[GlEPTB;MD6wNVM{PiEQvF2= M{C0VHNCVkeHUh?=
KM12 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWz[oxKSzVyPUCuNFE{PDhizszN M1ywR3NCVkeHUh?=
GI-1 M{PP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjHfYFSUUN3ME2wMlAyOzh|IN88US=> M1\6SXNCVkeHUh?=
LS-411N M4DrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLmTWM2OD1yLkCxOFA4KM7:TR?= MmDNV2FPT0WU
ES8 M2ezNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3OWXNKSzVyPUCuNFE1QTRizszN MnnBV2FPT0WU
SNU-C2B NViwc3o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC3OHdSUUN3ME2wMlAyPTJ4IN88US=> MXnTRW5ITVJ?
CESS MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLXRoFKSzVyPUCuNFE3ODJizszN NYHHS2xUW0GQR1XS
697 M3XPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEG2Olgh|ryP Mm\TV2FPT0WU
NCI-H1963 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEG2O|Mh|ryP MWHTRW5ITVJ?
IA-LM NVPO[IhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zNPWlEPTB;MD6wNVY5QCEQvF2= NFezO25USU6JRWK=
SW954 NFG2OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HO[2lEPTB;MD6wNVcxPSEQvF2= M1i5NHNCVkeHUh?=
RL95-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDlTWM2OD1yLkCxO|M5KM7:TR?= MlHBV2FPT0WU
LXF-289 M3nJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrTV4pKSzVyPUCuNFE4PyEQvF2= MmTFV2FPT0WU
OCUB-M MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki1TWM2OD1yLkCxPFI3KM7:TR?= NInRcHJUSU6JRWK=
RKO M4CzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe1TWM2OD1yLkCxPVg4KM7:TR?= MXXTRW5ITVJ?
LOUCY MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPifmJzUUN3ME2wMlAzODVizszN NWK3dXJEW0GQR1XS
NOS-1 NUHye4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYruVlZ6UUN3ME2wMlAzODl|IN88US=> Mn3WV2FPT0WU
A4-Fuk MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHrW5BZUUN3ME2wMlAzOjF6IN88US=> MlTCV2FPT0WU
A388 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInrRllKSzVyPUCuNFIzOjdizszN MWLTRW5ITVJ?
TE-9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnQTWM2OD1yLkCyNlYyKM7:TR?= M2DNfnNCVkeHUh?=
KURAMOCHI MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEKyPFUh|ryP MnTDV2FPT0WU
KALS-1 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnke4JKSzVyPUCuNFI{OzhizszN MWDTRW5ITVJ?
HOP-62 NVfmdWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fLUGlEPTB;MD6wNlQzKM7:TR?= MYHTRW5ITVJ?
RPMI-8402 NIOyWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjsZXJKSzVyPUCuNFI2ODhizszN M4KxdXNCVkeHUh?=
TE-1 NUT6eHBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3ETWM2OD1yLkCyOVEzKM7:TR?= MnToV2FPT0WU
CCRF-CEM NH\PcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfKNIsyUUN3ME2wMlAzPTR|IN88US=> NYSweXpTW0GQR1XS
HUTU-80 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDxTWM2OD1yLkCyOlI1KM7:TR?= NWf0cXdJW0GQR1XS
NCI-H1648 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLyTWM2OD1yLkCyOlQ4KM7:TR?= Mn7FV2FPT0WU
HCE-4 NWDUd|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:5W2lEPTB;MD6wNlY5OiEQvF2= NX33bmVYW0GQR1XS
ETK-1 NXq4[Go5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O2TWlEPTB;MD6wNlc{PiEQvF2= MUXTRW5ITVJ?
TE-15 NX75XVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEK3N|gh|ryP MXXTRW5ITVJ?
BE-13 NFe2bHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjHTWM2OD1yLkCyO|Qh|ryP MYDTRW5ITVJ?
KE-37 NHX5PWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\OTWM2OD1yLkCyO|QyKM7:TR?= MYXTRW5ITVJ?
NCI-H1355 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O1b2lEPTB;MD6wNlc5OyEQvF2= MkPrV2FPT0WU
TE-11 M4K5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjJcYpKSzVyPUCuNFI5ODlizszN Mkj2V2FPT0WU
BL-70 NIfYO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfadlRtUUN3ME2wMlAzQDV5IN88US=> MmDPV2FPT0WU
ES6 NHHmSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7lTmRKSzVyPUCuNFI5QDFizszN MmrSV2FPT0WU
GT3TKB NU\UOmxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLuTWM2OD1yLkCyPVU{KM7:TR?= NHHVfotUSU6JRWK=
LB647-SCLC MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljCTWM2OD1yLkCzNVk2KM7:TR?= M{fsbHNCVkeHUh?=
NB13 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnQXGhKUUN3ME2wMlA{OzF4IN88US=> MXrTRW5ITVJ?
ST486 M1noW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD4ZWx6UUN3ME2wMlA{OzN5IN88US=> NVG0Npo3W0GQR1XS
NCI-H82 NYjNcJQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPIdVhZUUN3ME2wMlA{OzR|IN88US=> M{\tOHNCVkeHUh?=
NTERA-S-cl-D1 NXHHXJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\2TWM2OD1yLkCzN|k6KM7:TR?= MYDTRW5ITVJ?
ES4 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvlNHFKSzVyPUCuNFM1PjNizszN NWWxW2hbW0GQR1XS
SK-NEP-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WwWGlEPTB;MD6wN|Q6QSEQvF2= MkHLV2FPT0WU
Becker MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMEO1OVUh|ryP M{DMW3NCVkeHUh?=
A101D NEHPfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTGW2NKSzVyPUCuNFM4PDhizszN MlPTV2FPT0WU
SK-UT-1 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hq[2lEPTB;MD6wN|c4PCEQvF2= M2K4NnNCVkeHUh?=
SW982 NYPQZ|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GyeWlEPTB;MD6wN|c6KM7:TR?= M3HHd3NCVkeHUh?=
TE-10 M4LOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnCe|dVUUN3ME2wMlA1ODR4IN88US=> MXnTRW5ITVJ?
OVCAR-4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[0clNKSzVyPUCuNFQxPTlizszN NETQe49USU6JRWK=
KP-N-YS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vDSGlEPTB;MD6wOFA5PSEQvF2= MV3TRW5ITVJ?
BL-41 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\LPHNGUUN3ME2wMlA1OTJ3IN88US=> NUW3bZk5W0GQR1XS
MZ1-PC NWLOVll[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHHTWM2OD1yLkC0NVI4KM7:TR?= NEDCRmNUSU6JRWK=
PF-382 NYjC[nk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;VcYpKSzVyPUCuNFQyQThizszN MWTTRW5ITVJ?
MOLT-13 NWrtSYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy4dHNKSzVyPUCuNFQzOzhizszN NVmzUHNEW0GQR1XS
HCC1599 NETNdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDaTWM2OD1yLkC0NlU5KM7:TR?= MWPTRW5ITVJ?
IST-MEL1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXOdJpKSzVyPUCuNFQ1PDJizszN MlHLV2FPT0WU
LU-139 M1HsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkixTWM2OD1yLkC0OFQzKM7:TR?= MnXxV2FPT0WU
MS-1 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjrT4ZKSzVyPUCuNFQ4ODFizszN NXS1V2VqW0GQR1XS
MFH-ino Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\vPVRKSzVyPUCuNFUxODNizszN Mo\LV2FPT0WU
IMR-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEWwNlEh|ryP MXPTRW5ITVJ?
TE-5 NYnVe5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HwbWlEPTB;MD6wOVA3OyEQvF2= MmDmV2FPT0WU
DJM-1 NXPWfIdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonYTWM2OD1yLkC1NVQzKM7:TR?= NVTWbXNPW0GQR1XS
NB17 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DL[WlEPTB;MD6wOVIxPyEQvF2= MYnTRW5ITVJ?
KARPAS-45 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHhSpExUUN3ME2wMlA2OzV6IN88US=> M2DpZnNCVkeHUh?=
TGBC1TKB NHP1VYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmyOoZKSzVyPUCuNFU1ODVizszN M{PKbHNCVkeHUh?=
ML-2 M4LkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjiTJpbUUN3ME2wMlA2PDF2IN88US=> NV63VmZKW0GQR1XS
no-10 NEjuZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP5eGVKSzVyPUCuNFU1PzRizszN NFfPO2lUSU6JRWK=
CTV-1 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rsWWlEPTB;MD6wOVUxOiEQvF2= M4fSNnNCVkeHUh?=
SJSA-1 NXiySFI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG0TWM2OD1yLkC1OVIh|ryP NF;PcWdUSU6JRWK=
HC-1 M3y2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfIO3lKSzVyPUCuNFU2QTdizszN NGHxXmJUSU6JRWK=
TE-12 M3\JUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEW2NVMh|ryP Mn\SV2FPT0WU
KY821 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2xTWM2OD1yLkC1OlMzKM7:TR?= NGfkdZZUSU6JRWK=
TALL-1 NUjy[oR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DUcWlEPTB;MD6wOVcxQCEQvF2= NHfwVWVUSU6JRWK=
DEL M1XoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDhb3pKSzVyPUCuNFU4ODlizszN NEP6PHBUSU6JRWK=
TE-6 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEW3NlIh|ryP MWLTRW5ITVJ?
SK-LMS-1 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEW4NFUh|ryP M17zSXNCVkeHUh?=
EW-1 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fuWmlEPTB;MD6wOVg{PyEQvF2= NEfqc|RUSU6JRWK=
8-MG-BA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[4TWM2OD1yLkC1PFUyKM7:TR?= MWHTRW5ITVJ?
NALM-6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fUNGlEPTB;MD6wOVk4OyEQvF2= NIfWV2NUSU6JRWK=
LB771-HNC M3;vfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEW5O|kh|ryP M4q4WXNCVkeHUh?=
HT-144 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljtTWM2OD1yLkC2NVMh|ryP MYfTRW5ITVJ?
KM-H2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom0TWM2OD1yLkC2NlIyKM7:TR?= M2\GbHNCVkeHUh?=
SF268 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rkbGlEPTB;MD6wOlI5PiEQvF2= M4DsPXNCVkeHUh?=
RS4-11 NXjsdFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUToOpp2UUN3ME2wMlA3OzB2IN88US=> MVXTRW5ITVJ?
MHH-PREB-1 M3ziR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTZTWM2OD1yLkC2N|E6KM7:TR?= Ml:xV2FPT0WU
ATN-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfGUmVKSzVyPUCuNFY{PDVizszN NWfTU5VnW0GQR1XS
BB30-HNC NHvJWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjOVW1KSzVyPUCuNFY1OzZizszN NXL6[YlJW0GQR1XS
CPC-N Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPzT2lKSzVyPUCuNFY2OjRizszN MmHiV2FPT0WU
NB1 Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzwN2pKSzVyPUCuNFY3OTNizszN NGrnfWtUSU6JRWK=
KS-1 NWKwbVZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj3TpVKSzVyPUCuNFY4PDhizszN M1jLWHNCVkeHUh?=
RXF393 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwME[3OlQh|ryP MmX1V2FPT0WU
IST-SL2 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXaW5NXUUN3ME2wMlA4ODB2IN88US=> NFjKb|JUSU6JRWK=
GI-ME-N NUOwN2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD1yLkC3Nlg3KM7:TR?= M4jqWHNCVkeHUh?=
VA-ES-BJ M1nXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj2WJNWUUN3ME2wMlA4PDd3IN88US=> MWrTRW5ITVJ?
NCI-H1581 NVPW[|R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml22TWM2OD1yLkC3OFc5KM7:TR?= NVjVUmNvW0GQR1XS
U-266 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16ybmlEPTB;MD6wO|Q6PyEQvF2= NX\IfZFUW0GQR1XS
DMS-114 M4Xxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3dnhKSzVyPUCuNFc2OjhizszN NHzJV2hUSU6JRWK=
NCI-H187 M3voUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[5U|hKSzVyPUCuNFc4OjZizszN M2jqTHNCVkeHUh?=
SW962 NX3aRlRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zNWmlEPTB;MD6wO|g{QSEQvF2= NWPOW4ZMW0GQR1XS
MONO-MAC-6 NV\3WpZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXu[HNKSzVyPUCuNFc6QDZizszN MXHTRW5ITVJ?
MOLT-16 M3TjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXwTWM2OD1yLkC4NVIyKM7:TR?= MVjTRW5ITVJ?
KNS-42 M{LKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTaWm9IUUN3ME2wMlA5OTZzIN88US=> NETmWppUSU6JRWK=
CMK NXHzTZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn1RlBKSzVyPUCuNFgzOjVizszN MnzuV2FPT0WU
Ramos-2G6-4C10 NVHiWGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXryOGhRUUN3ME2wMlA5OjJ3IN88US=> Mo\KV2FPT0WU
Daudi MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DrVGlEPTB;MD6wPFI2PiEQvF2= MVHTRW5ITVJ?
NCI-H510A NU\iT5BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXUSJRpUUN3ME2wMlA5OzN4IN88US=> MkfhV2FPT0WU
LB831-BLC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\CdmlEPTB;MD6wPFU3OSEQvF2= NXSxSVh1W0GQR1XS
HEL M4Wxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO5TWM2OD1yLkC4OlY5KM7:TR?= NEK0fWVUSU6JRWK=
LU-134-A NXK1XoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEi3NFgh|ryP NIm0dGRUSU6JRWK=
NCI-H1694 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT0RVhKSzVyPUCuNFg4PDRizszN MUHTRW5ITVJ?
KGN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7KTWM2OD1yLkC4O|U6KM7:TR?= MmDmV2FPT0WU
A253 M1X1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWOyUZoxUUN3ME2wMlA5QDJ{IN88US=> NUCwTJA5W0GQR1XS
DG-75 NGGzWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjWVY9KSzVyPUCuNFg6OjJizszN NI\K[GdUSU6JRWK=
MOLT-4 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnq[ZV4UUN3ME2wMlA5QTh|IN88US=> NVLwPGlEW0GQR1XS
NCI-SNU-5 NXv3bYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn6OmFKSzVyPUCuNFkzPThizszN MULTRW5ITVJ?
ONS-76 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDkTpZKSzVyPUCuNFkzPzZizszN NWrWUoxFW0GQR1XS
NCI-H446 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M134XmlEPTB;MD6wPVQ3OiEQvF2= MU\TRW5ITVJ?
COR-L279 M3v2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\nfWlEPTB;MD6wPVU2PiEQvF2= M3LodXNCVkeHUh?=
Calu-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\iTWM2OD1yLkC5OVk5KM7:TR?= M3jEdnNCVkeHUh?=
BC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHiTWM2OD1yLkC5OlYzKM7:TR?= M4LtTnNCVkeHUh?=
NCI-H2126 M2rPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfOTWM2OD1yLkC5O|kyKM7:TR?= Mnu5V2FPT0WU
NCI-H1882 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XKfGlEPTB;MD6wPVgxQSEQvF2= NV3MXVJuW0GQR1XS
BB65-RCC NHrtRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMUCyPVQh|ryP NV3sZWxYW0GQR1XS
DU-4475 M2jVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fFNGlEPTB;MD6xNFQxPyEQvF2= NXHEbWxSW0GQR1XS
NCI-H526 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfZbIRKSzVyPUCuNVA1PCEQvF2= NHXHW25USU6JRWK=
NEC8 NUOxcIZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDOTWM2OD1yLkGwOVI2KM7:TR?= MoDNV2FPT0WU
NCI-H1304 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rSOmlEPTB;MD6xNFU6PCEQvF2= NUnZRW1vW0GQR1XS
L-540 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfUTWM2OD1yLkGwO|A5KM7:TR?= MYnTRW5ITVJ?
NCI-SNU-16 M3jzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrEZ|RKSzVyPUCuNVA4PDJizszN NVPnVVVSW0GQR1XS
HD-MY-Z NVG0ZZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvIeohOUUN3ME2wMlExQDV4IN88US=> NWjxcHFzW0GQR1XS
K-562 NWfONYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMUC4OVgh|ryP MknjV2FPT0WU
JAR MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;UTWM2OD1yLkGwPVI2KM7:TR?= NULDW3d7W0GQR1XS
MZ2-MEL NXvzWXlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2eyPGlEPTB;MD6xNVA2KM7:TR?= NYjsNJhvW0GQR1XS
L-363 NED4[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUGwO|kh|ryP NXi0ToZQW0GQR1XS
BV-173 NVTiV2doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHYUZFZUUN3ME2wMlEyOjR|IN88US=> MnGwV2FPT0WU
NCI-H524 NIPYeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMUGyO|Qh|ryP MULTRW5ITVJ?
EoL-1-cell NGP4V5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjHTWM2OD1yLkGxOlczKM7:TR?= NXT2WpFDW0GQR1XS
K052 NHj5NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrVb4UxUUN3ME2wMlEyPzF{IN88US=> M3[xPXNCVkeHUh?=
TK10 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrScGpKSzVyPUCuNVE4OjhizszN MkK0V2FPT0WU
KU812 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KzRWlEPTB;MD6xNlA1PCEQvF2= NE\sVGdUSU6JRWK=
RPMI-8226 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSy[2ZKSzVyPUCuNVIxPTJizszN MkfuV2FPT0WU
MZ7-mel MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O4O2lEPTB;MD6xNlI{PyEQvF2= MVLTRW5ITVJ?
SK-PN-DW MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TLfGlEPTB;MD6xNlI5PyEQvF2= MWfTRW5ITVJ?
SR Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrVVWNEUUN3ME2wMlEzPDRzIN88US=> M2S0XnNCVkeHUh?=
RPMI-6666 NX[1UpBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XxN2lEPTB;MD6xNlc1OyEQvF2= MnzCV2FPT0WU
no-11 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMUK4Olkh|ryP M4joenNCVkeHUh?=
EW-3 NH3oXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7FNIduUUN3ME2wMlEzQDl|IN88US=> NGrtWWlUSU6JRWK=
LAMA-84 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLWTWM2OD1yLkGzNVg4KM7:TR?= NFTkclBUSU6JRWK=
HT M{\3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX5eZZvUUN3ME2wMlE{PTd2IN88US=> M2[2[HNCVkeHUh?=
KP-N-RT-BM-1 M4nsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXIdllKSzVyPUCuNVM3OTJizszN Mmm0V2FPT0WU
NCI-H747 M{jXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\z[GlEPTB;MD6xN|ch|ryP NH\2e|dUSU6JRWK=
NCCIT MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fTbGlEPTB;MD6xN|k{QSEQvF2= M17tVnNCVkeHUh?=
MLMA M2XjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjCUJRQUUN3ME2wMlE1OTZ5IN88US=> NFq1VJhUSU6JRWK=
LP-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu3TGV7UUN3ME2wMlE1OjRizszN NH3rNmxUSU6JRWK=
CAL-148 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nzfWlEPTB;MD6xOFQ5OyEQvF2= M{Ltd3NCVkeHUh?=
GB-1 NH6xeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK2epBKSzVyPUCuNVQ2OjZizszN MWLTRW5ITVJ?
COR-L88 NHPUbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXqTWM2OD1yLkG0PFAzKM7:TR?= NHjFOGhUSU6JRWK=
NKM-1 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzvV3NKSzVyPUCuNVQ6ODZizszN MVfTRW5ITVJ?
NB5 NF\xdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\Mb3VvUUN3ME2wMlE2PDZ{IN88US=> NVG2SnlyW0GQR1XS
SH-4 NXPL[lRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTITWM2OD1yLkG1OFY3KM7:TR?= M13ZfHNCVkeHUh?=
EM-2 M2G2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV30ZmtbUUN3ME2wMlE2PDZ5IN88US=> MlOyV2FPT0WU
TGBC24TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMUW2OVkh|ryP M3LQ[XNCVkeHUh?=
SCLC-21H M{noe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMUW3NFIh|ryP MXnTRW5ITVJ?
COLO-684 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUW3NlEh|ryP MkD0V2FPT0WU
KINGS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:wTWM2OD1yLkG1PVEh|ryP Mn7lV2FPT0WU
LS-123 M3zWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXSWmJKSzVyPUCuNVU6OTdizszN NIXyS2dUSU6JRWK=
MC116 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzaS4VHUUN3ME2wMlE3OTV6IN88US=> M4jQcHNCVkeHUh?=
SU-DHL-1 NYjHbWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTmSXpKSzVyPUCuNVYzODZizszN MlPnV2FPT0WU
NCI-H64 NVnl[oZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrLSnhKSzVyPUCuNVY{PDdizszN MUjTRW5ITVJ?
HCE-T NX;DNFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPMXXhQUUN3ME2wMlE3PTB2IN88US=> MnqzV2FPT0WU
LOXIMVI Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPkOJpZUUN3ME2wMlE3QTR7IN88US=> NHvuV4xUSU6JRWK=
ARH-77 M2DUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPUfFVKSzVyPUCuNVc{PzlizszN MmnnV2FPT0WU
DOHH-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMUe2O|Ih|ryP NWmzdoN2W0GQR1XS
COLO-320-HSR MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fWXWlEPTB;MD6xPFE2PCEQvF2= M1HRenNCVkeHUh?=
NB6 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrXTmF1UUN3ME2wMlE5PTZ4IN88US=> MmPwV2FPT0WU
L-428 M{P5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXnTYxiUUN3ME2wMlE5QDF|IN88US=> NVX1OmcxW0GQR1XS
SNB75 M3vCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi0NJBKSzVyPUCuNVg5OjRizszN NWHZXphEW0GQR1XS
NCI-H2141 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMUmwNVEh|ryP NFXtenpUSU6JRWK=
KARPAS-299 NXLSO4tVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXXTWM2OD1yLkG5NlQyKM7:TR?= M2HDenNCVkeHUh?=
LC4-1 NU[weVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMUm1NFIh|ryP MUjTRW5ITVJ?
UACC-257 NFW0PWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG1N2lKSzVyPUCuNVk6PDdizszN M2C4NXNCVkeHUh?=
EVSA-T NGe3bmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMkCzNVIh|ryP NFTuUVVUSU6JRWK=
JiyoyeP-2003 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMkC0O|ch|ryP NVHPUJJLW0GQR1XS
NCI-H720 Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj1bm41UUN3ME2wMlIxPTJ3IN88US=> MWPTRW5ITVJ?
GAK MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fMXGlEPTB;MD6yNVE5QSEQvF2= NVPYTWR1W0GQR1XS
HH MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXvXJJKSzVyPUCuNlE1ODVizszN MmjkV2FPT0WU
NCI-H1436 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DwUmlEPTB;MD6yNVQ3PCEQvF2= M1zmb3NCVkeHUh?=
GR-ST NETwT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHLSZBUUUN3ME2wMlIyPDh6IN88US=> NHPBUotUSU6JRWK=
BC-1 NGXQTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT2V41MUUN3ME2wMlIzPjF4IN88US=> NF7kRmpUSU6JRWK=
SIG-M5 M{nQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMkK3Nlch|ryP NVO5XVE1W0GQR1XS
NCI-H345 NHjBPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPE[FdwUUN3ME2wMlI{QDB3IN88US=> NYjCe2tTW0GQR1XS
OPM-2 NHHBOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrmclcxUUN3ME2wMlI{QDh{IN88US=> NVnDV3FwW0GQR1XS
LB1047-RCC M3TUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjBNHJKSzVyPUCuNlQ1OSEQvF2= NVfifXlXW0GQR1XS
CTB-1 NELKcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16zSWlEPTB;MD6yOFQ6OyEQvF2= NYe2OG5MW0GQR1XS
A3-KAW M2XQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\JUJI6UUN3ME2wMlI2OzRzIN88US=> MUPTRW5ITVJ?
SF126 NVnZUXJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMkWzPFMh|ryP MV7TRW5ITVJ?
KARPAS-422 NXHNVm85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHhN4pKSzVyPUCuNlU1OzVizszN MVLTRW5ITVJ?
MEG-01 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml72TWM2OD1yLkK1Olc{KM7:TR?= M1r3SHNCVkeHUh?=
NCI-H209 NFH1WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDoTWM2OD1yLkK2N|c1KM7:TR?= MonZV2FPT0WU
SBC-1 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLjTWM2OD1yLkK2OUDPxE1? Mm\ZV2FPT0WU
K5 NV\pUYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK2TpVKUUN3ME2wMlI3QTh2IN88US=> M3HIenNCVkeHUh?=
QIMR-WIL MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMkexOVUh|ryP NHLyUYhUSU6JRWK=
NMC-G1 M4rOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS3UI5KSzVyPUCuNlgzOTdizszN M330eHNCVkeHUh?=
IST-MES1 M37rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jtNmlEPTB;MD6yPVI{QCEQvF2= MkT2V2FPT0WU
SW684 NHnudIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[2NYdKSzVyPUCuN|AxPDdizszN M4ruSXNCVkeHUh?=
MV-4-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu1cJEzUUN3ME2wMlMxPzh6IN88US=> MVTTRW5ITVJ?
LAN-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T5ZmlEPTB;MD6zNVU4OiEQvF2= NFPyZXBUSU6JRWK=
RH-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPlSWtSUUN3ME2wMlMyQDdzIN88US=> NIfXTmNUSU6JRWK=
CP66-MEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwM{G4O|gh|ryP MlHKV2FPT0WU
EC-GI-10 NG\2RVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\Y[FFwUUN3ME2wMlMzQTh5IN88US=> NVjqXHNvW0GQR1XS
GDM-1 NVfjSJV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEny[21KSzVyPUCuN|MxPTlizszN MUPTRW5ITVJ?
IST-SL1 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH76VGdKSzVyPUCuN|Q6OTRizszN M4jMeHNCVkeHUh?=
KMOE-2 NVmxeXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwM{WxO|Uh|ryP MonDV2FPT0WU
OS-RC-2 NUXPdGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwM{W1OFQh|ryP M{PzOHNCVkeHUh?=
HDLM-2 NIT4RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfjTWM2OD1yLkO3PFE1KM7:TR?= NUi4WpNqW0GQR1XS
DSH1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXiUphsUUN3ME2wMlM5PjNzIN88US=> M3O5VXNCVkeHUh?=
LS-1034 NUe4PWg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwM{i5OVQh|ryP M3XQdXNCVkeHUh?=
LB373-MEL-D NHXKbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSzTWM2OD1yLkO5NVk4KM7:TR?= MXTTRW5ITVJ?
GOTO M{SweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy1elBtUUN3ME2wMlQzOTF6IN88US=> MX\TRW5ITVJ?
MRK-nu-1 M3L3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPIfph6UUN3ME2wMlQzOjB3IN88US=> NHH6T2lUSU6JRWK=
SK-MM-2 NVLaT|J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr5b|J1UUN3ME2wMlQ{PDR{IN88US=> NVrqbIQ3W0GQR1XS
BOKU M2HXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C0eGlEPTB;MD60N|c6OiEQvF2= MkXQV2FPT0WU
NOMO-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNEO4OkDPxE1? NFHvenJUSU6JRWK=
J-RT3-T3-5 M2Tq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLiTWM2OD1yLkS0PFc5KM7:TR?= NHrZVHBUSU6JRWK=
COLO-668 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqeGlEPTB;MD60OVY3QCEQvF2= M{fFZ3NCVkeHUh?=
SF539 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwNEi2PFQh|ryP MXLTRW5ITVJ?
LB2518-MEL NHvYbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j4emlEPTB;MD60PVcxOyEQvF2= MnfhV2FPT0WU
TE-441-T M2r4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfhS2xkUUN3ME2wMlUxOTJizszN MWDTRW5ITVJ?
MDA-MB-134-VI NFi2fVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNUC5NlEh|ryP MoHNV2FPT0WU
SCC-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwNUG4O|Mh|ryP NVflSWcxW0GQR1XS
KLE NV;tSlVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfLdHNKSzVyPUCuOVIyPzFizszN MUTTRW5ITVJ?
LB2241-RCC MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXpRoZTUUN3ME2wMlUzPTJ3IN88US=> M1r0OnNCVkeHUh?=
NCI-H1417 M{\EV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwNUO0N|Uh|ryP MV\TRW5ITVJ?
NCI-H2081 M4nXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD3TWM2OD1yLkW4OlEyKM7:TR?= NYW3NFdHW0GQR1XS
NCI-H1522 NW[2cIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNUmzPFMh|ryP NUHmcZFnW0GQR1XS
NCI-H889 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNUm4OFQh|ryP MnrvV2FPT0WU
CGTH-W-1 M3vsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXxXVZWUUN3ME2wMlYxPzV3IN88US=> Mn7MV2FPT0WU
EB-3 M{PIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwNkGxOVMh|ryP M4W0NXNCVkeHUh?=
D-336MG NH\wcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwNkG3PVEh|ryP Ml;DV2FPT0WU
LC-1F NULoUYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XrOWlEPTB;MD62NlU6OiEQvF2= Ml62V2FPT0WU
MHH-NB-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXxbFBYUUN3ME2wMlY{QDBzIN88US=> MVvTRW5ITVJ?
SK-N-FI NH7HXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNkO5NUDPxE1? MmizV2FPT0WU
NCI-H69 M1;oW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnEV2E3UUN3ME2wMlY1QDd7IN88US=> NGLzPIJUSU6JRWK=
SCH M2HlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXFTWM2OD1yLk[2NFI{KM7:TR?= MoroV2FPT0WU
LS-513 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTNTWM2OD1yLk[3NlU6KM7:TR?= MUnTRW5ITVJ?
CP67-MEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrITpFrUUN3ME2wMlY4PTl4IN88US=> MorFV2FPT0WU
GCIY M3HiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjIVYhtUUN3ME2wMlcxOzZ|IN88US=> M3L1dXNCVkeHUh?=
SHP-77 NWfjXpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfETWM2OD1yLkewO|M1KM7:TR?= M1PBVHNCVkeHUh?=
EHEB NFqzT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTDSZpKSzVyPUCuO|E5PTRizszN MXTTRW5ITVJ?
D-247MG M3ryZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\SPW1lUUN3ME2wMlc{OjN{IN88US=> NH7id5ZUSU6JRWK=
Raji NUm4d4kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37qfmlEPTB;MD63OFk5QSEQvF2= NUXvV5JqW0GQR1XS
MPP-89 NFvWPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TvT2lEPTB;MD63OVk4QCEQvF2= M3rNbXNCVkeHUh?=
EKVX M1W0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS5XYxKSzVyPUCuO|kxPzNizszN Ml;OV2FPT0WU
HCC2218 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv0b3lMUUN3ME2wMlc6OTNzIN88US=> NU\tSm1WW0GQR1XS
KNS-81-FD MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDHTXFKSzVyPUCuPFExOTFizszN Mni0V2FPT0WU
HCC2157 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrvTWM2OD1yLki0PVUyKM7:TR?= NXzMXm9uW0GQR1XS
BT-474 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwOEi4OVQh|ryP M1\1VnNCVkeHUh?=
NCI-H748 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj1coVKSzVyPUCuPVEzKM7:TR?= NWLmdJhpW0GQR1XS
EW-24 NYD5SFZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ftdWlEPTB;MD65NlAxOiEQvF2= NY[xclZYW0GQR1XS
D-263MG NVL1XGFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn2TWM2OD1yLkm0OVEzKM7:TR?= NIXtco1USU6JRWK=
OMC-1 M1OwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwOU[zO|Mh|ryP NIT5OmtUSU6JRWK=
NCI-H2196 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\semlEPTB;MD65O|c4PyEQvF2= MUHTRW5ITVJ?
HAL-01 NIPtXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTPTWM2OD1yLkm5PFczKM7:TR?= NFzBRVlUSU6JRWK=
NCI-H2107 NXWwcIp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfRTJFwUUN3ME2xMlAyQDV2IN88US=> MYnTRW5ITVJ?
LB996-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\pWYFKSzVyPUGuNFgxPTFizszN NFfFeGdUSU6JRWK=
NCI-H1395 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLoTWM2OD1zLkGwOlch|ryP MVPTRW5ITVJ?
CHP-126 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXESGpYUUN3ME2xMlE3OTl7IN88US=> NV6x[FBFW0GQR1XS
NB69 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XsNGlEPTB;MT6yOlE1QCEQvF2= MX7TRW5ITVJ?
CAS-1 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwM{SyN|Eh|ryP MYPTRW5ITVJ?
JVM-3 NH;uPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXPTWM2OD1zLkS3PFU2KM7:TR?= NWjmWoI5W0GQR1XS
DMS-153 M2nHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLXdoFDUUN3ME2xMlU4Pjd2IN88US=> MULTRW5ITVJ?
SK-MEL-2 NVzqbWRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DCd2lEPTB;MT63NVc5QSEQvF2= MkS5V2FPT0WU
NCI-H1155 NYDiSnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzGTWM2OD1zLkezOlc3KM7:TR?= MW\TRW5ITVJ?
NCI-H1092 M1G0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofHTWM2OD1zLke2NVgzKM7:TR?= M1vVdnNCVkeHUh?=
LU-165 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DnVmlEPTB;MT64OlQ4PiEQvF2= M2TLS3NCVkeHUh?=
HL-60 NXOw[FFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwOUm5NFgh|ryP NInzTVNUSU6JRWK=
REH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfQO|hEUUN3ME2yMlAxPTh{IN88US=> MX;TRW5ITVJ?
JVM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTmdZNjUUN3ME2yMlA3OTN3IN88US=> Mlz4V2FPT0WU
MN-60 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDYU2FwUUN3ME2yMlE4OzB6IN88US=> M{W5VnNCVkeHUh?=
SCC-15 NITkcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTITWM2OD1{LkKwNlch|ryP NHrMe5VUSU6JRWK=
SNU-C1 M4eyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKS2ZKSzVyPUKuNlE{PDNizszN MkPUV2FPT0WU
SK-MEL-1 NGTF[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5dVJiUUN3ME2yMlMzODR5IN88US=> NYXJdmlxW0GQR1XS
TGW M4fVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTFXVRKSzVyPUKuN|UxOjdizszN MlizV2FPT0WU
CA46 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwN{W5Olch|ryP NFu2dGJUSU6JRWK=
NCI-H23 M3PqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvORoVKSzVyPUKuPFA4QTFizszN M4PLTnNCVkeHUh?=
MMAC-SF NGCyWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3FTGJpUUN3ME2yMlg3PjJ6IN88US=> MnS3V2FPT0WU
NCI-H2171 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwMEO0OFgh|ryP NUS1XVRbW0GQR1XS
A704 M4rrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nxN2lEPTB;Mz6xOFE6PCEQvF2= NWPYco81W0GQR1XS
DB MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXObnFHUUN3ME2zMlI2PTd4IN88US=> MkDtV2FPT0WU
NCI-H719 MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzhZ4JHUUN3ME2zMlMxOzh2IN88US=> M3TBT3NCVkeHUh?=
MC-CAR NHXkUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNwNUS4NVch|ryP NGi0T2dUSU6JRWK=
SIMA MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjJVZBMUUN3ME2zMlU5PDF4IN88US=> MmKzV2FPT0WU
SW872 NETm[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz5d2luUUN3ME2zMlc5OTBzIN88US=> NFXHTW1USU6JRWK=
HCC1187 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrHTWM2OD1|Lke4N|E2KM7:TR?= NH3kdXBUSU6JRWK=
EW-13 M2G3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ntfGlEPTB;Mz64N|QyPyEQvF2= Mmm1V2FPT0WU
NCI-SNU-1 NEDhb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwMkG5PVkh|ryP M1XzeHNCVkeHUh?=
NCI-H226 NVi4cFA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\qTWM2OD12LkOzOlA3KM7:TR?= MUnTRW5ITVJ?
RPMI-8866 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRwM{[wNlkh|ryP MoPxV2FPT0WU
OCI-AML2 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXsXHBKSzVyPUSuOVUzOyEQvF2= NYLTTIprW0GQR1XS
LU-65 NH\O[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13UNmlEPTB;ND65N|A{OyEQvF2= MnvBV2FPT0WU
SK-N-DZ NX;iPWppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTVwNkO0OlUh|ryP MVrTRW5ITVJ?
NB14 NUWwNJZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTBRmdLUUN3ME21Mlk4OTN3IN88US=> MWrTRW5ITVJ?
COLO-829 M4HlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTZwM{OzOVkh|ryP NIjqWllUSU6JRWK=
MHH-CALL-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvjUJFMUUN3ME22MlUyPTB6IN88US=> M{PTVXNCVkeHUh?=
NCI-H1770 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTZwNk[5NFQh|ryP NHr3cVNUSU6JRWK=
ECC4 M3XNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDvWoU5UUN3ME22MlgzOTd7IN88US=> NUjIZYZsW0GQR1XS
A498 Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTZwOEexPVIh|ryP MWrTRW5ITVJ?
DMS-79 NHXnTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojnTWM2OD15LkC0OVEzKM7:TR?= MlrVV2FPT0WU
P30-OHK MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj2fIdrUUN3ME23MlIyQTB4IN88US=> MlHLV2FPT0WU
D-502MG MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXtb3E4UUN3ME23Mlk5OzZizszN NVHoS2ZqW0GQR1XS
RCC10RGB MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRThwME[yPEDPxE1? Mn;IV2FPT0WU
U-698-M MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\aeYFpUUN3ME24MlI6OjJ4IN88US=> NHTWdWdUSU6JRWK=
BB49-HNC NWfkfYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjL[YNKSzVyPUmuOFIzPjVizszN NVfvPIl7W0GQR1XS
ES1 NXfmO2N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfw[YJ[UUN3ME25MlY5QTV4IN88US=> NWLC[ndiW0GQR1XS
MFM-223 NGTzbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULDUFdvUUN3ME2xNE46QTJ5IN88US=> MWfTRW5ITVJ?
C2BBe1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHteVhEUUN3ME2xNU4{PTJ|IN88US=> M1\pSHNCVkeHUh?=
EB2 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HwdGlEPTB;MUKuOlg5OSEQvF2= MYXTRW5ITVJ?
C8166 NYnoenJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljXTWM2OD1zMz64N|A{KM7:TR?= NXPEWG1PW0GQR1XS
ES3 NH;5XWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17TWmlEPTB;MUOuPVk4PyEQvF2= MUHTRW5ITVJ?
NCI-H1650 NYTJ[VBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL0VYY5UUN3ME2xOk4{PzZ3IN88US=> MXLTRW5ITVJ?
Mo-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXNOYpKSzVyPUG3MlQxOjlizszN M3THcHNCVkeHUh?=
NB7 M1rqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIXIpKSzVyPUG3Mlc1PjdizszN NIHqWFlUSU6JRWK=
ES7 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG1UldKSzVyPUG5MlU2ODdizszN NETBWGJUSU6JRWK=
ES5 M3r1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\YcotKSzVyPUKxMlc3PzFizszN NFLJW|VUSU6JRWK=
MSTO-211H M3naTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJzLki4OVgh|ryP NIDPb4RUSU6JRWK=
U-87-MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPJWHJKSzVyPUK1MlE6PjZizszN NF7MfYxUSU6JRWK=
THP-1 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC5cVBSUUN3ME2yPU44OjBzIN88US=> NHfDVYlUSU6JRWK=
NB10 NH\hZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rBU2lEPTB;M{CuNlY6PCEQvF2= NHPzbY1USU6JRWK=
NH-12 NWP2SGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDxTWM2OD1|Mz6yNFE4KM7:TR?= NVrmPI41W0GQR1XS
COLO-824 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXyU5NKSzVyPUO0MlExODZizszN MUjTRW5ITVJ?
SKM-1 NFP2N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN5Lki0NlIh|ryP M2LldXNCVkeHUh?=
NCI-H1838 NV3KdHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TrXWlEPTB;M{iuN|c6PyEQvF2= MWXTRW5ITVJ?
RL M4fYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnyxTWM2OD1|OT6yOFc4KM7:TR?= NY\DbIw1W0GQR1XS
COLO-800 M2rrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P6cGlEPTB;NECuNFc4OyEQvF2= Ml;1V2FPT0WU
KG-1 NFjBWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH0TWM2OD12MD64PVU2KM7:TR?= MYnTRW5ITVJ?
TUR M1PQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDGNIhKSzVyPUSxMlY{QTlizszN MmLNV2FPT0WU
LNCaP-Clone-FGC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\pTWM2OD12MT65NFE4KM7:TR?= NH3QcWVUSU6JRWK=
NCI-H322M NUfJ[WxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXOdWdKSzVyPUSyMlU6QDRizszN MUfTRW5ITVJ?
LNCaP  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmzTWM2OD17MT6zJI5O M1LLR|I2PTB3MUe0
C4-2 NFm1bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRThibl2= NYfYeHZCOjV3MEWxO|Q>
JURKAT NW[wTmFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm3N2YzPCCq NVnBW2NlUUN3ME20NVYvPjZibl2= NES4dGIzPDVzOUm5OS=>
MOLT-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKyOEBp M2XjVmlEPTB;Mki1N{42KG6P MVuyOFUyQTl7NR?=
REH MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSyOEBp NH\acGVKSzVyPUK4O{43QCCwTR?= M4H4W|I1PTF7OUm1
NALM-6 M4nlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXCN2NkOjRiaB?= M1LLe2lEPTB;M{SzN|Ahdk1? NGSxTXozPDVzOUm5OS=>
RS 4;11 M2TheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjHU5ozPCCq NGO4S4lKSzVyPUWxPU4xPSCwTR?= MUSyOFUyQTl7NR?=
697 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3OlI1KGh? NXTUeJdlUUN3ME2yNVA4NjFibl2= M{XIdlI1PTF7OUm1
SIL-ALL NFvQb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;rNlQhcA>? M3uzbmlEPTB;MUm5Mlc4KG6P NEnpV|AzPDVzOUm5OS=>
CEM MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXiNlQhcA>? MkDRTWM2OD13Mj6xPEBvVQ>? MoHBNlQ2OTl7OUW=
P12 M1X3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuyOEBp NW\weHNCUUN3ME2zPU4zPyCwTR?= NHrR[4UzPDVzOUm5OS=>
NALM-16 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HBSFI1KGh? NFjmNYtKSzVyPUm2MlI5KG6P MmTsNlQ2OTl7OUW=
JURKAT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjJOot5PDhiaB?= NUHKfY9MUUN3ME2xOE45PCCwTR?= MnzBNlQ2OTl7OUW=
MOLT-4 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzxdZVRPDhiaB?= M{LsNWlEPTB;Mk[uOkBvVQ>? M4mzN|I1PTF7OUm1
REH MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHa[5p7PDhiaB?= NYq5elUzUUN3ME20OE44OSCwTR?= NWD4VGg{OjR3MUm5PVU>
NALM-6 M2HEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULxbodLPDhiaB?= M2P2fGlEPTB;MkOuNlYhdk1? MlzpNlQ2OTl7OUW=
RS 4;11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnZOnk1QCCq NF63VYpKSzVyPUG2OE4zQCCwTR?= M4CxN|I1PTF7OUm1
697 NFL6ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV60PEBp NILLU|ZKSzVyPUOwOU4{KG6P NVvuUJU2OjR3MUm5PVU>
SIL-ALL NH36VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33kU|Q5KGh? NX[3NYNYUUN3ME23OE43OiCwTR?= NU\yOFNYOjR3MUm5PVU>
CEM NYWyRY93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXPV|BYPDhiaB?= MXzJR|UxRTJ2LkW1JI5O MV2yOFUyQTl7NR?=
P12 NWXXT|BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly3OFghcA>? M{DSdmlEPTB;MUiuOFYhdk1? NHP3UI8zPDVzOUm5OS=>
NALM-16 NGPWfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zXU|Q5KGh? MUPJR|UxRTZ|LkK0JI5O NVvVRmZFOjR3MUm5PVU>
JURKAT MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp M2DWOGlEPTB;Mz62OUBvVQ>? NWLVUJA2OjR3MUm5PVU>
MOLT-4 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTnO|IhcA>? NULwPYpNUUN3ME23MlM6KG6P M3LYbFI1PTF7OUm1
REH NX75W|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXYZlI4OiCq M4DVc2lEPTB;MU[uNFEhdk1? Mn7TNlQ2OTl7OUW=
NALM-6 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[3NkBp MYTJR|UxRTFwN{igcm0> NF;yVJkzPDVzOUm5OS=>
RS 4;11 NFT4SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmeIM4OiCq NILNbGhKSzVyPUSuN|ghdk1? NF3BNFczPDVzOUm5OS=>
697 NF3hVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7BfnBGPzJiaB?= Ml\VTWM2OD15ND6yPEBvVQ>? NUK2VoRtOjR3MUm5PVU>
SIL-ALL M4PGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\OblczKGh? MmXHTWM2OD15LkKgcm0> M{Tt[VI1PTF7OUm1
CEM M{DFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH0[ph[PzJiaB?= MWHJR|UxRTVwNEKgcm0> NF;mZ|QzPDVzOUm5OS=>
P12 M{DVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGzO|IhcA>? MYHJR|UxRTZwM{egcm0> MmPlNlQ2OTl7OUW=
NALM-16 NVPtfHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[yb2Q4OiCq MoXZTWM2OD15Nz63N{BvVQ>? MViyOFUyQTl7NR?=
Y79 NYTSdoJxSXCxcITvd4l{KEG|c3H5 NH3HWHgyNTVyIH7N NHSzS3AyOi9{NDDo NFj3T|hFVVOR M3Hk[Ilv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=> MnzvNlQ{PjZ4NkW=
WER-Rb-1 NHi3S5JCeG:ydH;zbZMhSXO|YYm= M1fHNFEuPTBibl2= NXjx[G9oOTJxMkSgbC=> NHm5VllFVVOR M3H4bolv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=> NGf3bHIzPDN4Nk[2OS=>
G7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPnR5N5UUN3ME2zMlMhdk1? Mkj2NlQzODR5M{O=
G166 NEnJXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrhb|JKSzVyPUeuNEBvVQ>? MX[yOFIxPDd|Mx?=
CB660 NWL5WpFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTHTWM2OD14LkSgcm0> NFHEb5czPDJyNEezNy=>
CB1117 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Ts[WlEPTB;MUWuOkBvVQ>? NHPrbZozPDJyNEezNy=>
KB-3-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrWSmZ2UUN3ME2xMlQ5KMLzIECuOVMhdk1? MmnnNlM6PjJ2NEW=
KB-8-5-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK0b2UyUUN3ME21MlAyKMLzIEKuNFEhdk1? NFHoemwzOzl4MkS0OS=>
KB-C-1 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF4Lke2JOKyKDRwNUGgcm0> NGHXR4kzOzl4MkS0OS=>
KB-V-1 NGDlb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjIPVBKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?= NV7tVlF2OjN7NkK0OFU>
OVCAR-8 NVPrNWRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnGTWM2OD15LkG5JOKyKDNwNkCgcm0> MnvsNlM6PjJ2NEW=
NCI-ADR-RES NVnCPXdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\jd2lEPTB;MUK3N{4{OCEEsTCxPVEvOjBibl2= M4\zRVI{QTZ{NES1
MCF7 NXn0eGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\VUo52UUN3ME21MlEyKMLzIEGuOFchdk1? M1[1VFI{QTZ{NES1
MCF7-FLV1000 M{DBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm1SXJKSzVyPUO5N{4yQCEEsTC3OE45OyCwTR?= NU\ZWWFPOjN7NkK0OFU>
S1 M17ubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPoTWM2OD1{ND6zNEDDuSB2Lke1JI5O M{i5b|I{QTZ{NES1
S1-M1-80 NYrKeWRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjjfHNUUUN3ME2yOlEvODZiwsGgOFgvOjVibl2= MnTlNlM6PjJ2NEW=
CORL-23/P M13PRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7jTWM2OD12LkO4JOKyKDFwMkWgcm0> M4n2eVI{QTZ{NES1
CORL-23/R MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrJTWM2OD13LkG2JOKyKDFwOEOgcm0> MnHzNlM6PjJ2NEW=
NIH3T3 NH;PT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3xTWM2OD12MD62NEDDuSB2Lkm3JI5O MoLiNlM6PjJ2NEW=
NIH3T3-G185 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ2MUOuOFAhyrFiNEKzMlY3KG6P NYfBR3k3OjN7NkK0OFU>
pcDNA-HEK293 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0[G9DUUN3ME2yMlc2KMLzIECuOlchdk1? MVKyN|k3OjR2NR?=
MDR19-HEK293 NHnIUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL1VoE3UUN3ME24OU42OCEEsTCxN{43PyCwTR?= NFHzd5czOzl4MkS0OS=>
R482-HEK293 NXK5TZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfsTWM2OD1{NT65O{DDuSB2Lkm1JI5O M{G3eFI{QTZ{NES1
MRP1-HEK293 NUXHPVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn35TWM2OD1{Lkm5JOKyKDFwNEmgcm0> MkH3NlM6PjJ2NEW=
SF188 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XSNFExNTFyMDDuUS=> NV2ydGRXOjRvOU[gbC=> MYfEUXNQ NEL0OItqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK= M4G3d|I{QDh5NkS1
T98G MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m4TVExNTFyMDDuUS=> MXyyOE06PiCq M4npTmROW09? NUPyNY5icW6qaXLpeJMh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdi1iZHXw[YRmdnRibXHucoVz M37qRVI{QDh5NkS1
DU145 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPEUXNQ NUjVO2RMUUN3MPMIwFYxKG6P NIrMelQzOzh6NESyPC=>
LNCaP  M3y0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXaSG1UVw>? MWjJR|Ux6oj:N{Wgcm0> NY\IW2tZOjN6OES0Nlg>
PC3 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrUSG1UVw>? MWfJR|Ux6oj:MUe1JI5O NFPqcIwzOzh6NESyPC=>
RT4 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLkcFFuUUN3ME2yO{4zOSCwTR?= Ml\0NlM4QTJ4M{m=
5637 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\xVWlEPTB;NEWuOFchdk1? Mn33NlM4QTJ4M{m=
T24 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nXdmlEPTB;N{muNVIhdk1? MYGyN|c6OjZ|OR?=
MCF7  NU\HUJJSTnWwY4Tpc44hSXO|YYm= NHLuPWYyODBibl2= NWWwPXRVOSCq NILTUWFFVVOR NVTw[lRkemWmdXPld{B1cGViaX7keYN1cW:wIH;mxsBIemWkMT|CpHNoczFuwrDQd|ItyqCVZYLwbY5iOyxiYX7kxsBYcXOyMh?= MVOyN|c4ODJ2NB?=
KB-V1  NHjnc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT1TWM2OD1|LkmyJO69VQ>? MVqyN|U6OzF7Nh?=
Hec50co M1;CZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37sdGlEPTB;NTDuUS=> NXn0UId1OjNzNE[2PFc>
MDA-MB-468 Moe0RZBweHSxc3nzJGF{e2G7 Mny0NU82NzFyIH7N NXXl[pFUOjRxNEivO|IhcA>? M{X2WmROW09? NEXYcolqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{D2PVI{OTR2Mkm0
MCF10A MXrBdI9xfG:|aYOgRZN{[Xl? MVyxM|UwOTBibl2= Mnj1NlQwPDhxN{KgbC=> MlXRSG1UVw>? MUfpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlXWNlMyPDR{OUS=
Huh-7 NYDoNY5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XGdlEwOTBxMUCwM|ExODBibl2= MVO0PEBp MojK[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBld3OnLXTldIVv\GWwdHz5 MlTQNlI4PDV3OEe=
Daoy  NXjFSpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTNNU45PzVvMkSwJI5O MlLWO|IhcA>? NXr6T2g4TE2VTx?= M2LpbWlEPTB;NTDuUS=> Mn\vNlI{QTB{N{m=
ONS-76 NXXOcXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O2NVEvQDd3LUK0NEBvVQ>? NFjDN|I4OiCq MnL6SG1UVw>? NEjhXHZKSzVyPUeuOUBvVQ>? NXfBV2lQOjJ|OUCyO|k>
SUM 149 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;0eVAuOTByIH7N M2XFOVczKGh? M3Ww[4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> MnH1NlI{ODl7M{m=
MDA-MB-231 M{XKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;tNE0yODBibl2= MXq3NkBp NXvHVodJcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz MmLQNlI{ODl7M{m=
HR5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[1NE0yODBibl2= MX[3NkBp NInGZ5BqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> MV[yNlMxQTl|OR?=
BT-474-M1 Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD0c24xNTFyMDDuUS=> NX71fIZvPzJiaB?= M163[YlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> NEj2Z5kzOjNyOUmzPS=>
AU565 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HuRlAuOTByIH7N MmXxO|IhcA>? NULmU|VDcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz MWOyNlMxQTl|OR?=
T47D NGPaZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTZXJZWOC1zMECgcm0> NETLRYk4OiCq NFHSUldqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> M2nzU|IzOzB7OUO5
MCF7 M4W0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPUdYsxNTFyMDDuUS=> NYjER2RDPzJiaB?= MmLGbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy NYnYZWdtOjJ|MEm5N|k>
HCT116p53(+/+) MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rXOlExNTFyMECgcm0> Mnn2NlQwPDhiaB?= M3LDd4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6KGG2IEK1JI5O MYeyNlI3OjF5MR?=
HCT116p53(-/-) NVG4WnU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojVNVAuOTByMDDuUS=> NH;WRmYzPC92ODDo MUfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=> NUXtV5V[OjJ{NkKxO|E>
HeLa  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWxNE0yODBibl2= M3PFXVQ5KGh? M1KyZWROW09? MYfJR|UxRTV{Lkmgcm0> MXWyNlA5ODJ|NR?=
HeLa  MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjofVFOOTBvMUCwJI5O M4DPWlczKGh? M3XyW2ROW09? MUXJR|UxRTVyLkWgcm0> MXOyNlA5ODJ|NR?=
GBC M2rtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[3NkBp MnrkTWM2OD1zND63PEBvVQ>? NHL6UokzOTl4NUezPS=>
GB-CL-1 NYDadpo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjwO|IhcA>? MVTJR|UxRTVwMkKgcm0> MUKyNVk3PTd|OR?=
Mz-ChA-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q2blczKGh? NHT6d3BKSzVyPUOuN|Ehdk1? NFvuUYQzOTl4NUezPS=>
TGBC1-TKB M3fE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L5RVE1PCCq M2rKWGlEPTB;Nj63NkBvVQ>? NWDyRVdROjF7NkW3N|k>
Wittier M2Sycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;aO|IhcA>? NFqyVWFKSzVyPUOuNlYhdk1? MmPaNlE6PjV5M{m=
H-1 M4DmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZR|czKGh? NG\VR2lKSzVyPUmuOVQhdk1? NWT5XHRZOjF7NkW3N|k>
HuH-28 NHjGcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjFO|V7PzJiaB?= MoLoTWM2OD1zMT6xPUBvVQ>? M1P5dVIyQTZ3N{O5
NEC NEC0O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy2VppIPzJiaB?= MYPJR|UxRTlwOUigcm0> MW[yNVk3PTd|OR?=
REB MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrWTFdGPzJiaB?= MVTJR|UxRTF|LkWxJI5O MnWzNlE6PjV5M{m=
CC-LP-1 NF\ITW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOO|IhcA>? M3HsN2lEPTB;NT64OEBvVQ>? NHvFTFYzOTl4NUezPS=>
CC-SW-1 M{PQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XDe|czKGh? M2nBWGlEPTB;OT61OUBvVQ>? NIDSPG0zOTl4NUezPS=>
EGI-1 NETMWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGw[VI4OiCq NEO3V5VKSzVyPUGwMlczKG6P MVqyNVk3PTd|OR?=
Sk-ChA-1 NWGxXoZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13QXFczKGh? M16yfGlEPTB;MUeuNkBvVQ>? NIPzRZAzOTl4NUezPS=>
TFK-1 NHT2N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nyblczKGh? Mn:2TWM2OD1zMz60OUBvVQ>? MYmyNVk3PTd|OR?=
786-O MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nKSFUuQDBibl2= MWq5OkBp NYDtdXVNUEOu MVXzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? NGnmdHEzOTZ2MkO3OC=>
A498 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPPSndUPS16MDDuUS=> M33SR|k3KGh? NEX3[4FJS2x? NHHleZR{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= M2C3b|IyPjR{M{e0
ACHN MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzORYtqPS16MDDuUS=> MnniPVYhcA>? NYXnfWlMUEOu MmrGd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P NEjoZnczOTZ2MkO3OC=>
Caki-1 NXHET5pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\PWJA2NThyIH7N MknFPVYhcA>? NETCb4lJS2x? M1v2W5N2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?= NVrZPVB6OjF4NEKzO|Q>
SN12C MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO1V|JKPS16MDDuUS=> M2rtd|k3KGh? MmT5TGNt MVvzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? MkjRNlE3PDJ|N{S=
HMC-1.1 M4Dyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvaZpUyNTFyMECgcm0> NF;wWIs4OiCq NX;WTlVocW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n NHXMWmwzOTJ2MkG4PS=>
HMC-1.2 Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTINU0yODByIH7N MYS3NkBp M4POc4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>? NWD1ZYd3OjF{NEKxPFk>
C2 NIL3V2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexMVExODBibl2= MmPxO|IhcA>? NH\WdWZqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmV? NXrVV5k3OjF{NEKxPFk>
CHP-212 NWfnVnFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3uZlJJOS1zMkWgcm0> NVLVNGRiOjRvMUKwJIg> M1m4fIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= NEDI[4UzOTF4OUK0Ni=>
IMR-32 M{TyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;yNU0yOjVibl2= M4XmXFI1NTF{MDDo MWXpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n MXOyNVE3QTJ2Mh?=
Kelly NWD6VnI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HMWFEuOTJ3IH7N NGfUS4wzPC1zMkCgbC=> MWTpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n Mn7PNlEyPjl{NEK=
SH-EP NFXRUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rZSlEuOTJ3IH7N M16yTFI1NTF{MDDo MXjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n M1nXd|IyOTZ7MkSy
SH-SY5Y MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;tfFJoOS1zMkWgcm0> NELiOmwzPC1zMkCgbC=> M4nKZolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MoPiNlEyPjl{NEK=
SK-N-AS NFjwRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf0T|EyOS1zMkWgcm0> MYKyOE0yOjBiaB?= NVXxUFRWcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> NF\GTW0zOTF4OUK0Ni=>
SK-N-BE M3TYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XxXVEuOTJ3IH7N Mlr1NlQuOTJyIHi= M2fIU4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MWiyNVE3QTJ2Mh?=
KG1 NHXwOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXuUVZKOS9zMD:xNFAhdk1? M4e5V|czKGh? NXzqcHFWTE2VTx?= MVrpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n M4\zTVE6PDV6M{W4
U937 NFHPSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn6dXcyNzFyL{GwNEBvVQ>? NEnNTXA4OiCq MmX6SG1UVw>? NYfvb2VpcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> MWqxPVQ2QDN3OB?=
CAL62 NHTQO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fBTVAvOS1zMECgcm0> Mnj2O|IhcA>? M3LmOGROW09? NF\ZXnFGSzVyPUGuOEBvVQ>? MV6xPVIzOzV3Mx?=
OCUT-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXNE4yNTFyMDDuUS=> MYq3NkBp M{L6RmROW09? M2T5OWVEPTB;Mj6zJI5O M2XPO|E6OjJ|NUWz
8505C M4DQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;INE4yNTFyMDDuUS=> MWK3NkBp NVfCPVlLTE2VTx?= M1LuRmVEPTB;Mz6yJI5O Mn3KNVkzOjN3NUO=
ACT-1 NUTCUVZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOzWGNUOC5zLUGwNEBvVQ>? NEnGd3k4OiCq NELT[GxFVVOR NWjnNZhmTUN3ME21MlQhdk1? MmjDNVkzOjN3NUO=
SW1736 NUnXS|I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PIcVAvOS1zMECgcm0> M3jxd|czKGh? NIPufm5FVVOR MVnFR|UxRTVwNjDuUS=> MlvRNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]

Protocol

Kinase Assay:[1]
+ Expand

Plk1 in vitro kinase assay:

Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:[1]
+ Expand
  • Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24 and 72 hours
  • Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
  • Dosages: ~50 mg/kg
  • Administration: Injection i.v. once or twice per week
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (191.69 mM)
DMSO 21 mg/mL (40.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 521.66
Formula

C28H39N7O3

CAS No. 755038-02-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?

  • Answer:

    For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products4

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID